A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of HL-1186 in Healthy Participants
Latest Information Update: 14 Apr 2025
At a glance
- Drugs HL-1186 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Shanghai Huilun Pharmaceutical
- 14 Apr 2025 New trial record